The Smart View 3D option is used as part of a head or whole body CT interventional procedure when the physician desires to obtain a visualization, 3D orientation, and localization of the needle in patients of all ages. SmartView 3D can automatically detect various sized needles during CT interventional procedures. SmartView 3D reconstructs and displays the traditional 2D images, and immediately thereafter additionally displays Multiple Planar Reconstruction images from a reconstruction in an orthogonal reference frame aligned with the needle 's orientation where the needle tip is at the origin. This additional information may aid in guidance and/or monitoring during interventional procedures.

Device Description

The GE SmartView 3D Option is for use with a GE CT system. SmartView 3D is an enhanced software option to the current SmartView Option application (predicate device: K973168). The SmartView 3D Option is designed to be used during CT-guided interventional procedures with the ability to detect needles and produce, in a needlebased geometry, orthogonal 3D reformats. SmartView 3D displays the oblique Multiple Planar Reconstruction (MPR) images of the needle and provides 3D information of the needle orientation. The SmartView Option is intended to be used during CT interventional procedures with either a continuous fluoro acquisition mode or a step-andshoot, single segment rotation acquisition mode, both of which create 2D axial images using the CT scanner's reference frame. When applied, the SmartView 3D option allows the user to acquire image data from a step-and-shoot, single segment rotation acquisition, which it then uses for the three MPR reconstructions (Needle-sagittal plane, Needle-axial plane, Needle-tip plane) that are able to be displayed simultaneously. SmartView 3D also displays 2D axial images reconstructed from the same acquisition. The 3D interventional viewports automatically update each time an acquisition is initiated with the foot pedal. SmartView 3D provides both the 2D axial reconstructions as well as the three MPR reconstructions which provide the physician with additional information for needle position visualization and localization for CT intervention procedures.

AI/ML Overview

The provided document, a 510(k) Premarket Notification Submission for the SmartView 3D Option, describes the device and its testing in relation to its substantial equivalence to a predicate device. However, it does not explicitly state quantitative acceptance criteria or a detailed study proving the device meets those criteria in the way typically expected for a detailed performance study with metrics like sensitivity, specificity, or AUC based on ground truth.

Instead, the submission focuses on substantial equivalence to an existing predicate device (SmartView Option K973168) and verification/validation testing to ensure design requirements are met and new safety/effectiveness concerns are not introduced.

Here's an analysis based on the available information regarding the SmartView 3D Option's performance:

1. Table of Acceptance Criteria and Reported Device Performance:

The document does not provide a table with specific, quantifiable acceptance criteria (e.g., minimum accuracy, sensitivity, or geometric precision for needle detection) and corresponding reported performance metrics.

Instead, the "acceptance criteria" are implied by the statements that:

"SmartView 3D is of clinical quality for its intended use and indications for use."
"SmartView 3D Option provides equivalent or better performance compared to SmartView Option."
"SmartView 3D... performs as well as devices currently on the market."
"System and subsystem verification have been successfully executed... which demonstrated the SmartView 3D option met design requirements."
"Engineering testing also included testing to substantiate the updated product claims and acceptance testing."
"No adverse effects or new questions of safety or effectiveness have been introduced."

2. Sample Size for Test Set and Data Provenance:

Test Set (Clinical Simulation Bench Testing): The document states that "Clinical simulation bench testing was performed by an experienced interventional radiologist using the current production Discovery CT590 RT (K132410) CT system with the current production SmartView option (K973168) and the new SmartView 3D option."
The test set consisted of "a variety of phantoms that are either used for training physicians on these types of procedures or, with the concurrence of the interventional radiologist, determined to be representative surrogates for evaluation of device performance."
- Sample Size: The exact number of phantoms or number of needle insertions/scans performed during this clinical simulation is not specified.
- Data Provenance: The "data" (phantom scans) were generated prospectively during the bench testing. The origin of the phantoms themselves is not stated (e.g., specific manufacturer, country).
Other Testing: "System and subsystem verification" and "Engineering testing" were also conducted, but details on sample sizes for these are not provided. These are generally internal tests.

3. Number of Experts and Qualifications for Ground Truth (Test Set):

Number of Experts: One "experienced interventional radiologist" was used for the clinical simulation bench testing.
Qualifications: "experienced interventional radiologist." No specific number of years of experience is given.
Role: This radiologist performed the needle biopsies on phantoms and concurred that the phantoms were "representative surrogates for evaluation of device performance." They also assessed that "SmartView 3D is of clinical quality for its intended use." This suggests the radiologist served as a primary evaluator of the device's performance in a simulated clinical setting.

4. Adjudication Method for the Test Set:

Based on the information, there was no formal adjudication method (e.g., 2+1, 3+1) described. Ground truth or performance evaluation appears to have been based on the assessment and concurrence of a single experienced interventional radiologist during the clinical simulation.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study:

No, a MRMC comparative effectiveness study was not explicitly conducted or reported. The testing involved a single experienced interventional radiologist, and the comparison was primarily between the new SmartView 3D option and the predicate device's capabilities (SmartView Option K973168) in terms of enhanced functionality, rather than a quantifiable improvement in human reader performance with and without AI assistance. The document states "External clinical evaluation was not needed to establish safety and effectiveness. All changes were able to be fully evaluated on the bench..."

6. Standalone (Algorithm Only) Performance Study:

Yes, a form of standalone testing was done implicitly. The "design of SmartView 3D adds a needle-specific detection algorithm to identify the needle, needle tip, and its 3D orientation." This algorithm's performance would have been evaluated during "System and subsystem verification" and "Engineering testing" to ensure it "met design requirements" and "substantiate the updated product claims." The clinical simulation tested the integrated system, including the algorithm's functional output, without directly involving human interpretation of images from the algorithm only vs. without the algorithm. The focus was on the system's ability to produce the new orthogonal 3D reformats based on the detected needle.

7. Type of Ground Truth Used (Test Set):

The ground truth for the clinical simulation bench testing on phantoms would have been the known physical location and orientation of the needles within the phantoms. This is established by the design of the phantoms and the controlled insertion of needles by the interventional radiologist. The radiologist's assessment of the device's ability to accurately visualize and localize these known needle positions acted as the validation of this ground truth.

8. Sample Size for the Training Set:

The document does not explicitly state the sample size for the training set used for the "needle-specific detection algorithm." As this is a 510(k) submission focused on substantial equivalence and verification testing, detailed information about algorithm training data (which usually includes its own set of ground truth) is often not included unless it's critical to demonstrate safety and effectiveness for a novel algorithm.

9. How Ground Truth for Training Set was Established:

This information is not provided in the document.

In summary, the submission emphasizes substantial equivalence, bench testing, and a clinical simulation with one expert on phantoms to demonstrate the device's functionality and safety, rather than a detailed performance study against specific, quantifiable acceptance criteria using a large, independently adjudicated test set.

Summary

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract symbol that resembles three human profiles facing to the right, with flowing lines beneath them.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

March 9, 2016

GE Hangwei Medical System Co., Ltd. % Lv Rui Regulatory Affairs Leader - Product MICT No.1, Yong Chang Street, Beijing Economic & Technical Development Area Beijing, 100176 CHINA

Re: K153429

Trade/Device Name: SmartView 3D Option Regulation Number: 21 CFR 892.1750 Regulation Name: Computed tomography x-ray system Regulatory Class: II Product Code: JAK Dated: January 26, 2016 Received: January 29, 2016

Dear Lv Rui:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

{1}------------------------------------------------

forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Michael D. O'Hara

For Robert Ochs, Ph.D. Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health

Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) K153429

Device Name

SmartView 3D Option

Indications for Use (Describe)

Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)	Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

Image /page/3/Picture/0 description: The image shows the General Electric (GE) logo. The logo consists of the letters "G" and "E" intertwined in a stylized, circular design. The logo is black and white and has a vintage look.

ﺮ

GE Hangwei Medical System Co.,Ltd 510(k) Premarket Notification Submission for SmartView 3D Option

510(k) Summary - SmartView 3D Option

In accordance with 21 CFR 807.92 the following summary of information is provided:

Date:	January 26, 2016
Submitter:	GE Healthcare GE Healthcare(GE Medical Systems, LLC)3000 N. Grandview Blvd W-1140Waukesha, WI 53188
Primary Contact Person:	Lv RuiRegulatory Affairs LeaderGE Healthcare (GE Hangwei Medical systems, Co, Ltd)Phone Number: (86)-10-58068888-70163Email: rui.lv@ge.com
Secondary ContactPerson:	Huy DoanRegulatory Affairs Director, MI&CTGE Healthcare (GE Medical Systems, LLC)Tel: 262-312-7751Fax: 262-364-2506e-mail: huy.doan@med.ge.com
Device Trade Name:	SmartView 3D Option
Common/Usual Name:	Needle Detection Software Application for ComputedTomography X-ray System
ClassificationNames:	Computed Tomography X-ray System 21CFR892.1750
Regulatory Class	II
Product Code:	JAK
PredicatedDevice(s):	SmartView Option (K973168)
Manufacturer(s):	GE Hangwei Medical Systems Co., LtdNo. 1 North Yong Chang North StreetBeijing Economy & Technology Development ZoneBeijing, 100176, ChinaGE Medical Systems, LLC (GE Healthcare)3000 N. Grandview Blvd.Waukesha, WI 53188

{4}------------------------------------------------

Image /page/4/Picture/0 description: The image shows the General Electric (GE) logo. The logo consists of the letters "GE" intertwined within a circular border. The letters are stylized and connected, creating a distinctive and recognizable emblem for the company.

GE Hangwei Medical System Co., Ltd 510(k) Premarket Notification Submission for SmartView 3D Option

Marketed Devices:

The GE SmartView 3D Option is of comparable type and substantially equivalent to the GE Healthcare's currently marketed SmartView Option (K973168).

Device Description:

SmartView 3D Option was developed on Discovery CT590 RT/Optima CT580 system (K132410). Additionally, following minor changes to the CT system software were made to include functionality for installation and operation of the SmartView 3D Option:

Intended Use:

The SmartView 3D option is intended to reconstruct and process images acquired during CT interventional procedures and display the interventional device within a variety of 2D and 3D reformats, providing information to the physician for visualization, orientation, and location.

Indications for Use:

The SmartView 3D option is used as part of a head or whole body CT interventional procedure when the physician desires to obtain a visualization, 3D orientation, and localization of the needle in patients of all ages. SmartView 3D can automatically detect various sized needles during CT interventional procedures. SmartView 3D reconstructs and displays the traditional 2D images, and immediately thereafter additionally displays Multiple Planar Reconstruction images from a reconstruction in an orthogonal reference frame aligned with the needle's orientation where the needle tip is at the origin. This additional information may aid in guidance and/or monitoring interventional procedures.

{5}------------------------------------------------

Image /page/5/Picture/0 description: The image shows the General Electric (GE) logo. The logo consists of the letters 'G' and 'E' intertwined in a stylized, cursive font. The letters are enclosed within a circular border, giving the logo a classic and recognizable appearance.

GE Hangwei Medical System Co .. Ltd 510(k) Premarket Notification Submission for SmartView 3D Option

Technology:

The SmartView 3D Option uses the same fundamental image acquisition, reconstruction, processing, and display technology as: the predicate device and in general, CT scanners and post-processing software devices that are designed to identify imaged objects

The design of SmartView 3D adds a needle-specific detection algorithm to identify the needle, needle tip, and its 3D orientation. This information is used with conventional multi-planar reformatting (MPR) as currently used in the predicate device. The reformatted images are produced in a needle-based geometry with an orthogonal 3D reference frame. SmartView 3D provides both the initial 2D axial reconstructions as well as the three MPR reconstructions that provide the physician with additional information for needle position visualization and localization for CT interventional procedures.

Adverse Effects on Health:

Potential electrical, mechanical, and radiation hazards are identified in risk management including hazard analysis and controlled by:

System verification and validation to ensure performance to specifications, Federal . Regulations, and user requirements.
. Adherence to software development lifecycle procedures (SDLC)
. Instruction for Use provided for the safe an effective use by users.

The device is designed and manufactured under the Quality System Regulations of 21 CFR820.

Determination of Substantial Equivalence:

The GE SmartView 3D Option is of comparable type and substantially equivalent to the SmartView Option (K973168).

Verification bench testing showed that the GE SmartView 3D Option provides equivalent or better performance compared to SmartView Option Product development and testing has demonstrated that no adverse effects or new questions of safety or effectiveness have been introduced.

External clinical evaluation was not needed to establish safety and effectiveness. All changes were able to be fully evaluated on the bench, and the testing did not reveal any new questions of safety or effectiveness. GE believes the totality of all of the combined changes is considered substantially equivalent to the unmodified device.

In addition, the substantial equivalence determination was also based on software documentation for a "moderate" level of concern device.

{6}------------------------------------------------

Image /page/6/Picture/0 description: The image shows a circular logo with the letters 'GE' intertwined in the center. The letters are stylized with curved lines and flourishes. The background of the circle is textured with small, decorative elements, possibly leaves or floral patterns. A thin, dark border outlines the circle, providing contrast against the white background.

GE Hangwei Medical System Co.,Ltd 510(k) Premarket Notification Submission for SmartView 3D Option

Summary of Additional Testing

System and subsystem verification have been successfully executed under GE's quality system, which demonstrated the SmartView 3D option met design requirements. Engineering testing also included testing to substantiate the updated product claims and acceptance testing.

Clinical simulation bench testing was performed by an experienced interventional radiologist using the current production Discovery CT590 RT (K132410) CT system with the current production SmartView option (K973168) and the new SmartView 3D option. This testing included performance of needle biopsies on a variety of phantoms that are either used for training physicians on these types of procedures or, with the concurrence of the interventional radiologist, determined to be representative surrogates for evaluation of device performance. The test procedures were executed and the test results demonstrated that SmartView 3D is of clinical quality for its intended use and indications for use.

Conclusion

SmartView 3D is an enhanced software option to the current SmartView Option. It does not result in any new safety risks and performs as well as devices currently on the market. The SmartView 3D Option for use on GE CT systems complies with the same or updated standards, as well as 21CFR 1020.30 and 1020.33 regulations as the predicate device. All verification and validation testing was successfully perform as well as additional engineering bench testing and also clinical simulation testing performed by an experienced interventional radiologist. Given the preceding, GE Healthcare believes the GE SmartView 3D Option is safe and effective, and performs in a substantially equivalent manner to the predicate device SmartView Option.

Regulation Number and Section

§ 892.1750 Computed tomography x-ray system.

(a)
Identification. A computed tomography x-ray system is a diagnostic x-ray system intended to produce cross-sectional images of the body by computer reconstruction of x-ray transmission data from the same axial plane taken at different angles. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II.